Kymera Therapeutics Inc (NAS:KYMR)
$ 50.94 1.09 (2.19%) Market Cap: 3.30 Bil Enterprise Value: 2.84 Bil PE Ratio: 0 PB Ratio: 3.69 GF Score: 50/100

Kymera Therapeutics Inc at UBS Global Healthcare Conference Transcript

May 23, 2022 / 05:15PM GMT
Release Date Price: $14.88 (+0.61%)
Eliana Rachel Merle
UBS Investment Bank, Research Division - Analyst

Good afternoon, everyone. I'm Ellie Merle. Welcome to the UBS Healthcare Conference. Very happy to have Kymera Therapeutics here with us today. Joining us from Kymera is Nello Mainolfi, President and CEO; Bruce Jacobs, Chief Financial Officer; and Jared Gollob, Chief Medical Officer. Thank you guys so much for joining us here today.

Questions & Answers

Eliana Rachel Merle
UBS Investment Bank, Research Division - Analyst

And I guess maybe to kick it off before we jump into the programs. High level, what is it about targeted protein degradation that you think is so exciting and potentially disruptive as a novel modality?

Nello Mainolfi
Kymera Therapeutics, Inc. - Co-Founder, President, CEO & Director

Thanks, Ellie. Thanks. Can you guys hear me? I think so. Thanks for inviting us. Actually, this is a great podium here. So let's start with what's not exciting about protein degradation. Now in reality, the opportunities -- we should

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot